Phase 2Data readout

SPY120 (Antibody Combination)

Ulcerative Colitis

SYRESpyre Therapeutics Inc

Expected catalystDecember 31, 2027Company guidance: Dec 31, 2027

Catalyst overview

Event details

Drug or asset: SPY120 (Antibody Combination)
Development stage: Phase 2
Event type: Data readout
Indication: Ulcerative Colitis

Research summary

What is being tracked?

This catalyst tracks a Phase 2 data readout for SPY120 (Antibody Combination) in Ulcerative Colitis. The expected timing is based on the latest available company guidance and may change.

Development notes

08/04/26:- SKYLINE Part B enrolling SPY120; induction data expected 2027.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

SPY120 (Antibody Combination)

Event details

What is being tracked?

Development notes

Primary source

Related pipeline programs

SPY003

SPY001 (α4β7)

SPY002 (SPY002-091) (TL1A)

SPY072 (SPY002-072)